5 years ago63 views
Dr. David Samadi, leading prostate cancer surgeon, discusses the U.S. government task force recommendation against annual PSA blood tests for healthy men. The prostate-specific antigen test is used to monitor a man’s PSA level, Dr. Samadi explains, it is not a prostate cancer diagnostic tool alone. PSA trend, or PSA velocity, should be monitored by an expert to identify a potential trend of elevation. Dr. Samadi believes this task force, which is not comprised of urologists or cancer experts, is making a dangerous call by recommending against the PSA. He encourages all men to get a baseline test at age 40 and continue annually after age 50, sooner if they are considered high risk. The PSA test has reduced the prostate cancer death rate by 44% and reduced the rate of metastasis through early diagnosis.